A series of videos from key opinion leaders that provides you insight on biosimilars

 
 

HERITAGE Trial Study Design

KOL: Hope S. Rugo, MD, FASCO
Overview:
Clinical data from HERITAGE Trial demonstrating effect of OGIVRI in HER2 positive patients

 

HERITAGE Trial Characteristics and Endpoints

KOL: Hope S. Rugo, MD, FASCO
Overview:
Clinical data from HERITAGE Trial demonstrating effect of OGIVRI in HER2-positive patients

 

HERITAGE Trial Safety

KOL: Hope S. Rugo, MD, FASCO
Overview:
OGIVRI offers equivalent safety as reference trastuzumab

 

Patient Case: Transferring your Patient

KOL: Vikram C Gorantla, MD
Overview:
A discussion on transition from reference trastuzumab to Biosimilar

 

Biologic, Biosimilars and the reference product

KOL: Ali McBride, PharmD
Overview:
Biologics, Biosimilars and Generics: Similarities and Differences

 

Biosimilar FDA Approval Pathway

KOL: Ali McBride, PharmD
Overview:
An understanding of FDA Approval Pathway for Biosimilars

 

Biosimilar into Clinical Practice

KOL: Vikram C Gorantla, MD
Overview:
An expert opinion on raising awareness in clinicians and patients about biosimilars

 

Patient Cases: Value-Based Oncology Care

KOL: Vikram C Gorantla, MD
Overview:
Key opinion leader discussing importance of patient education about biosimilars for making informed decisions